Browse the evidence

Obesity interventions generate substantial social value totaling $15 billion in net social value nationally.

Investing in obesity treatment can lead to significant societal benefits and economic value.

36.7% of adults with obesity but without diabetes had a prescription for semaglutide or tirzepatide that lasted less than 32 days.

Practitioners should be aware that a significant portion of patients may not adhere to GLP-1 RA prescriptions.

Persistent prescriptions (coverage for ≥336 days) were observed in 18.6% of participants.

A minority of patients may maintain long-term use of GLP-1 RAs, indicating potential for sustained treatment benefits.

The oleogel-in-oleogel system is capable of delivering fewer calories than fats and most oleogels while still providing essential fatty acids.

This could be a viable alternative for those looking to reduce caloric intake from fats.

Die aktuelle private Finanzierung von GLP-1-Rezeptoragonisten schränkt den Zugang für Menschen mit niedrigem sozioökonomischem Status ein.

Praktiker sollten die finanziellen Barrieren für den Zugang zu GLP-1-Rezeptoragonisten berücksichtigen.

Es gibt ethische Bedenken bezüglich der Verschiebung von Priorisierungen hin zu einer pharmakologischen Behandlung.

Praktiker sollten die ethischen Implikationen der Verschiebung hin zu pharmakologischen Behandlungen bedenken.

Future clinical trials are needed to clarify the mechanisms of benefit and define the role of weight-reduction therapies in obesity-related HFpEF.

Clinicians should be aware that ongoing research may further inform treatment strategies for obesity-related HFpEF.

Among patients who discontinued treatment, 72% did not demonstrate weight regain.

Clinicians may find that many patients can maintain weight after stopping GLP-1RA therapy.

Unerwünschte Wirkungen von Semaglutid sind gut dokumentiert, insbesondere gastrointestinale Beschwerden.

Ärzte sollten über die häufigsten Nebenwirkungen von Semaglutid informiert sein, um Patienten entsprechend zu beraten.

28.1% of eligible patients were current users of GLP-1 receptor agonists.

A notable proportion of eligible OSA patients are utilizing GLP-1 RAs, indicating potential treatment pathways.

Having Medicaid was associated with a lower likelihood of using GLP-1 receptor agonists among eligible patients.

Practitioners should be aware that socioeconomic factors, such as Medicaid coverage, may influence GLP-1 RA utilization.

There was no significant effect of whey or soy protein supplementation on lean body mass (LBM) or squat performance.

Practitioners should note that whey and soy protein may not significantly impact LBM or squat performance.

There is significant heterogeneity in the theoretical models and psychometric properties of existing tools assessing DEAB in athletes.

Practitioners should be cautious when interpreting results from various DEAB assessment tools due to their differing foundations and properties.

Resistance training frequency does not significantly affect changes in muscle mass.

Increasing resistance training frequency may not lead to greater muscle mass gains.

Supplementation often fails to improve protein balance or related physiological and performance outcomes under severe operational stress.

Practitioners should consider that protein supplementation may not be beneficial in high-stress operational environments.

Twenty percent of survey respondents had a high overall score on the Eating Attitudes Test (EAT-26), indicating high rates of disordered eating behaviors.

Practitioners should be aware of the prevalence of disordered eating in this population when addressing weight loss.

All interview participants reported engaging in and/or observing disordered eating behaviors in efforts to lose weight.

Understanding the social dynamics of disordered eating can inform interventions.

Disordered eating behaviors produced ripples of embodied experiences affecting family, friends, and coworkers of dieters.

Practitioners should consider the social context of disordered eating when developing support strategies.

Concerns exist regarding the cardiovascular safety of diets, particularly related to weight fluctuations and ketogenic diets.

Practitioners should be cautious about the cardiovascular implications of certain diets.

There is currently no definitive evidence that carbohydrate reduction per se durably lowers glycaemia in type 2 diabetes.

Caution against assuming that reducing carbohydrates will always improve glycaemic control.

Pre-intervention, the score of the survey of adherence to the Mediterranean diet was relatively low (7.44 ± 0.22 points).

Understanding baseline adherence levels can help tailor interventions effectively.

The T2D prediction model achieves 95.27% ROC-AUC, with 88.48% sensitivity and 87.19% specificity.

The model can be effectively used for early detection of T2D in diverse populations.

The model handles missing data naturally without complex preprocessing and imputation.

The model's ability to manage incomplete data makes it suitable for real-world applications.

The most beneficial type of diet for weight loss remains up for debate.

Practitioners should be aware of the ongoing discussions about diet effectiveness.